The PennZone

  • Home
  • Non-profit
  • Health
  • Books
  • Business
  • Entertainment
  • Legal
  • Marketing
  • Financial

Techdow USA Announces FDA Approval of Generic Lovenox®, (Enoxaparin Sodium – Preservative Free) In Prefilled Syringes
The PennZone/10224695

Trending...
  • Massive Acquisition Into Defense With STS for Virtuix Holdings; $40 Million Revenue Business Will Accelerate Growth Transforming Market Position
  • Orlando Real Estate Broker Bent Danholm Wins 2026 Goody Business Book Award for The Architecture of Demand
  • Commercial Sales for U.S.-Made, Preservative-Free Ketamine Amid Long-Runnin Shortage Following FDA Approval by NRx Pharmaceuticals, Inc
LANGHORNE, Pa. ~ Techdow USA Inc., a vertically integrated generic injectables company, has announced the FDA approval of Enoxaparin Sodium (Preservative Free) in Prefilled Syringes for the U.S. market.

Darren Alkins, Chief Executive Officer of Techdow USA, said "We are excited to bring this critical product to institutions, retail and other networks in need of a safe, affordable and reliable source of Enoxaparin. Our U.S. and global networks will help ensure reliable Enoxaparin supply, while offering competitive pricing."

The launch of Enoxaparin will compliment Techdow USA's existing Heparin Sodium injection business which was launched in 2022. According to IQVIA Health for the 12 months ending December 2022, Enoxaparin Sodium (Preservative Free) Prefilled Syringes had US brand and generic sales of approximately $550 million.

Techdow USA is among the fastest growing companies in the US generic pharmaceutical industry specializing in the sale of generic injectable pharmaceuticals and continues to work to expand their product portfolio and pipeline to better serve patient and customer needs. To report SUSPECTED ADVERSE REACTIONS, contact Hepalink USA, Inc./Techdow USA, Inc. at 1-888-355-1375 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. For more information visit www.techdowusa.com.*Lovenox® is a registered trademark of Sanofi-Aventis U.S. LLC

More on The PennZone
  • Montana Artist Ryan Jolley Receives Goodman Award at Mountain Oyster Club Art Show
  • Make Your Move to Luxury Living at Heritage at Hopewell with Rates Starting at Just 3.750% (5.803% APR)
  • Scott Glickson Joins STS Capital Partners as Managing Director
  • BREAKTHROUGH TROP2 Research Reveals New REQORSA® Opportunities as Roche Collaboration Strengthens Precision Lung Cancer Strategy
  • Scoop Social Co. Brings Its Signature Mobile Dessert Experience to Dallas–Fort Worth

Techdow USA Inc., a growing market leader in the generic injectables industry, has announced that its product Enoxaparin Sodium (Preservative Free) in Prefilled Syringes has been approved by the FDA for use in the U.S market. Darren Alkins, Chief Executive Officer of Techdow USA expressed his excitement about bringing this critical product to institutions, retail and other networks that need a safe, affordable and reliable source of Enoxaparin with competitive pricing options available through their U.S and global networks as well as being a long term reliable resource for the marketplace .

The launch of Enoxaparin compliments Techdow USA's existing Heparin Sodium injection business which was launched in 2022 with IQVIA Health reporting US brand and generic sales for this product at approximately $550 million for the 12 months ending December 2022 .

Techdow USA is continuing its efforts to expand its product portfolio and pipeline to better serve patient and customer needs while also being one of the fastest growing companies in the US generic pharmaceutical industry specializing in selling generic injectable pharmaceuticals . To report SUSPECTED ADVERSE REACTIONS contact Hepalink USA , Inc./Techdow USA , Inc . at 1 - 888 - 355 - 1375 or FDA at 1 - 800 - FDA - 1088 or www . fda . gov / medwatch . For more information visit www . techdowusa . com * Lovenox® is a registered trademark of Sanofi - Aventis U . S . LLC
Filed Under: Business

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • Boston Industrial Solutions Introduces the New Volta® M100 Pad Printing Machine
  • Not a Black Box Launches TalentOS, the First Talent Harness Operating System
  • A Diwali Celebration with Heritage at South Brunswick Residents & American Properties
  • Law Offices of Larry E. Bray, P.A. Wins Fourth District Appeal Clarifying Limits of Florida's Offer of Judgment Statute
  • Holiday Magic Returns to Downtown Downers Grove November 27-29
  • ET&T Named Philadelphia Business Journal Family-Owned Business Awards Honoree
  • What If the Greatest Gift This Holiday Season Came in a Dream of Your Loved One in Spirit?
  • 6,238 executives took new roles at US nonprofits from June to October 2026
  • Scoop Social Co. Brings Its Signature Mobile Dessert Experience to Minneapolis
  • LGF Lab Gas Flow Launches Fully Automatic Laboratory Gas Changeover Manifold System with Ultra High Purity Gas Regulator Valve
  • Woodside Village Joins Corner Property Management Following CMP Acquisition
  • 20-Year Crash Cost of Signalized RC3 Cloverleaf Could Exceed $25 Million
  • Record Q3 Revenue and Gross Profit Delivered: Revenue Surges 40%, Gross Margin Soars to 36% & Adjusted EBITDA Loss Narrows 64% for Cycurion, Inc $CYCU
  • Inaugural 12 Trees of Christmas gala raises $525,000 for DMG research and family support
  • BitTitan Expands MigrationWiz with SharePoint Sites Migration and Simplified Collaboration Licensing
  • Olympic champion Katie Moon to compete at Pole Vault in Paradise in Key West
  • Smith Strong Merges With Gravis Law, Bringing Gravis Law to Virginia
  • Angela's Boutique Highlights Self-Care Gifts for Philadelphia Holiday Shoppers
  • Turkish Engineer Who Cracked Wall Street's Algorithm Launches Hermes AI Analyzer
  • UK Financial Ltd Launches MayaSwap On MAYA CHAIN To Facilitate UKFLMS-For-Gold Swaps, Officially Transforming UKFLMS From Meme Into A Real-World Asset

Popular on PennZone

  • ALight Technology And Services Limited Advances Through Peachscore + Dealum Accelerator and Join LvlUp Labs - 182
  • Hunter's Garage Teams Up With The Small Batch for a Free Thanksgiving Meal - 173
  • WebDrafter Welcomes Dreamwork Exteriors as a New Marketing Client - 140
  • Conservative Latinos for PA PAC Endorses Stacy Garrity for Governor: "Pennsylvania's Latino Families Need a Leader Who Delivers" - 111
  • Communities In Schools of Eastern Pennsylvania Honors United Way and Local Leaders - 102
  • Charlie Shaw and Patrick Carragher win SEO Agency of the Year 2026
  • RAS AP Consulting Advances 1099 Education and Readiness Initiative Through IFOL Training and Finance Technology Showcase
  • Alan Hamilton of Shiver Hamilton Campbell Inducted as a Fellow of the American College of Trial Lawyers
  • Pastor Carlton L. Aiken Sr. Celebrates 55 Years with "Sermonic Selections"
  • No Bounds Digital Acquires Draidel's HubSpot Agency Business, Expanding Reach and Capabilities

Similar on PennZone

  • Scott Glickson Joins STS Capital Partners as Managing Director
  • BREAKTHROUGH TROP2 Research Reveals New REQORSA® Opportunities as Roche Collaboration Strengthens Precision Lung Cancer Strategy
  • Scoop Social Co. Brings Its Signature Mobile Dessert Experience to Dallas–Fort Worth
  • Loud! OOH Launches UK's First Free Planning Tool for UK Outdoor Advertising Budgets
  • Boston Industrial Solutions Introduces the New Volta® M100 Pad Printing Machine
  • Scoop Social Co. Brings Its Signature Mobile Dessert Experience to Minneapolis
  • Record Q3 Revenue and Gross Profit Delivered: Revenue Surges 40%, Gross Margin Soars to 36% & Adjusted EBITDA Loss Narrows 64% for Cycurion, Inc $CYCU
  • Entrepreneur Nouho M Kanneh Talks Family, Faith and a $37 Million Portfolio in New Interview
  • Massive Acquisition Into Defense With STS for Virtuix Holdings; $40 Million Revenue Business Will Accelerate Growth Transforming Market Position
  • Commercial Sales for U.S.-Made, Preservative-Free Ketamine Amid Long-Runnin Shortage Following FDA Approval by NRx Pharmaceuticals, Inc
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us